ACRS
ACRS
US00461U1051
Aclaris Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±93.1% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.

Beta (Market Relation)
0.88x
Defensive
Volatility (5Y p.a.)
93.1% p.a.
5-Year Horizon
Max Drawdown (5Y)
-96.5%
5-Year Horizon
Sharpe Ratio
-0.31
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +99.5%
3 Years 105.6% -89.3% -0.15 -13%
5 Years 93.1% -96.5% -0.31 -26.7%
10 Years 110.8% -98.0% -0.18 -17.2%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Elevated Short-Term Volatility: 3Y volatility (105.6%) is noticeably higher than the 5Y average (93.1%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (93.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -98.0% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
10 ISS Score: 10 / 10
Audit Risk
7 ISS Score: 7 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
7.49
ende